Dr. John Cush RheumNow
46 minutes 25 seconds ago
Small series of 5 Idiopathic inflammatory myopathy (IIM) pts Rx w/ obinutuzumab for refractory myositis (2 antisynthetase syndr, 1 DM, 2 overlap myositis). 4/5 patients achieved complete response. Lung improved/stabilized in ILD patients. Two required second obinutuzumab cycle. https://t.co/ev9qlEO04l
Dr. John Cush RheumNow
2 hours 46 minutes ago
Ro52 Abs in idiopathic inflammatory myopathies (IIM). From 2,126 IIM China/Japan pts, Ro52 positivity was common (46%), esp in MDA5+ DM & anti-synthetase syndr (ASyS) & was assoc w/ high freq of ILD, rapidly progressive ILD, and poor prognosis. https://t.co/TA4gSnZax1 https://t.co/riYs5YJwQV
Dr. John Cush RheumNow
16 hours 46 minutes ago
QD Clinic: RA, IBD and Frank's sign
Daric Mueller, PA-C, St. Clair Shores, MI, presents a case called, "Rheumatoid Arthritis, IBD and Frank's Sign", as part of RheumNow's "The Obesity Imperative" campaign presented in September 2026.
https://t.co/XMD0b35fiu https://t.co/9WUdZKAR0w
Dr. John Cush RheumNow
18 hours 16 minutes ago
QD Clinic: The Weight Behind Delay in Diagnosis
Dr. Antoni Chan, London, discusses a case of a patient with ankylosing spondylitis whose weight delayed the diagnosis and treatment of AS. This QD Clinic is presented as part of RheumNow's "The Obesity Imperative" campaign, https://t.co/fDozAaX64j
Dr. John Cush RheumNow
20 hours 31 minutes ago
EBR Journal Club: Dapirolizumab Pegol in SLE (PHOENYCS GO)
The EBR Journal Club Companion applies my adapted JAMA approach to critical appraisal to an important rheumatology RCT. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How https://t.co/kereLii5J6
Dr. John Cush RheumNow
21 hours 46 minutes ago
“ABCDE” Approach to Difficult-to-Treat Rheumatoid Arthritis
The proposed approach to D2T-RA is based on the EULAR definition (having failed 2 or more b/tsDMARDs). It is estimated that up to 20% of RA patients meet this D2T-RA definition and can be plagued by active or https://t.co/o39IREvjI4
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. New drugs approved, new drugs halted and some drugs out of control. Ready to test your knowlege? Take this week's quiz!
Dr. John Cush RheumNow
23 hours 45 minutes ago
Cochrane systematic review of LBP Rx (8 RCTs, 501 cLBP pts) show that Lumbar supports may result in a small reduction in pain intensity if given w/ NSAIDs, but may offer little to no benefit for pain intensity & disability if used alone. Insufficient evidence to support their https://t.co/6Vq4CPXLvE
Dr. John Cush RheumNow
1 day 1 hour ago
NY Times reports Gallop poll: 15% Americans have used a wt-loss drug (11% currently taking) - up from 3% in 2024. These have been approved for use in NIDDM, weight loss, liver Dz, CV risk reduct. & sleep apnea. Also obesity in USA is fell to 36.4%, after peak of 39.9% in 2022. https://t.co/ghxUEcuoGr
Dr. John Cush RheumNow
1 day 2 hours ago
NEJM images: Jaccoud’s arthropathy is a chronic, deforming;from laxity of the ligaments & tendons (not damage to bone & cartilage). Deformities are reducible & no erosions on Xray. Jaccoud’s mimics RA, but most seen w/ SLE. https://t.co/99WDNcpT5c https://t.co/77zAjpQh9A
The American College of Physicians (ACP) in July 2026 published its first living clinical guideline addressing pharmacologic management of overweight and obesity in nonpregnant adults in outpatient settings. The guidelines importance is driven by striking epidemiology: 59% of the global population and 68.5% of US adults now have overweight or obesity.
Dr. John Cush RheumNow
1 day 18 hours ago
Korean retrospective study compared NIDDM pts Rx w/ SGLT2 inhibitor (n 552,065) vs sulfonylurea (1,480,092) showed SGLT2 inhibitors were assoc w/ a signif 11% lower risk of incident autoimmune rheumatic disease (HR 0.89). Diff of −6.50 per 100K PYs over median ~9 mos F/U. https://t.co/uTiCjejkjL
Dr. John Cush RheumNow
1 day 19 hours ago
Lupus Research Alliance has awarded >$2 million in 2026 awards to studying innovative lifestyle interventions for people living with lupus. This includes studies on ginger supplementation, physical activity, and a whole health online programs https://t.co/C45y9laeHN https://t.co/6ifbPMWNt9
A meta-analysis of Janus kinase (JAKi) inhibitors clinical trials in rheumatoid arthritis (RA) has shown higher BMI was associated with poorer responses and a reduced treatment benefit with JAK inhibitors in RA patients.
